GOP presses Biden on canceled $142M contract for COVID-19 therapies

Published



Senate Republicans are demanding answers from the Biden administration about a federal contract signed with KPMG last year to promote monoclonal antibody treatments that they argue did little to forestall shortages of the therapeutics, which were badly needed as thousands died of COVID-19.

The Biden administration entered into a contract worth about $142 million with the accounting firm in March 2021 that was meant to help accelerate access to monoclonal antibody treatments for COVID-19 patients. But several Republicans on the Senate Health Committee, including Tommy Tuberville (R-AL), argue that the pricey deal did nothing to increase the supplies of the treatments, particularly during a national shortage last year. Now, they say the Biden administration is snubbing the committee and withholding information about the purpose and outcome of the costly contract.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.